Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

MBI and Breast Tomosynthesis Screening Accuracies in Patients With Dense Breast Tissue

This study has been withdrawn prior to enrollment.
Sponsor:
Information provided by (Responsible Party):
Gamma Medica, Inc.
ClinicalTrials.gov Identifier:
NCT02013726
First received: December 9, 2013
Last updated: August 22, 2014
Last verified: August 2014

December 9, 2013
August 22, 2014
April 2015
October 2017   (final data collection date for primary outcome measure)
Sensitivity/Cancer detection [ Time Frame: 12 months ] [ Designated as safety issue: No ]
Sensitivity being the number of scans read or labeled positive (by radiologist) divided by the total cancers confirmed by pathology results (i.e. biopsy).
Same as current
Complete list of historical versions of study NCT02013726 on ClinicalTrials.gov Archive Site
Specificity [ Time Frame: 12 months ] [ Designated as safety issue: No ]
Specificity being the total number of scans read or labeled as negative (by a radiologist) divided by number of total women without cancer. This "ground truth" of a true negative will involve in a second negative imaging scan at 12 months (follow-up exam).
Same as current
Not Provided
Not Provided
 
MBI and Breast Tomosynthesis Screening Accuracies in Patients With Dense Breast Tissue
Pilot Study: Dedicated Dual Head Molecular Breast Imaging Compared to Breast Tomosynthesis for Evaluation of Patients With Type 3 or 4 Mammographic Breast Density

Primary:

In women with heterogeneous or dense breast tissue (mammographic types 3 and 4), MBI (Molecular Breast Imaging) will detect more breast cancers and have greater sensitivity in detecting breast cancer than breast tomosynthesis.

Secondary:

  1. In women with heterogeneous or dense breast tissue, the specificity of MBI in correctly classifying subjects without breast cancer will be non-inferior to breast tomosynthesis.
  2. In women with heterogeneous or dense breast tissue, the area under the receiver operating characteristic (ROC) curve for MBI will be non-inferior or superior to breast tomosynthesis.
  3. Combining the use of MBI and breast tomosynthesis will provide performance superior to either technology alone, as manifest by a superior ROC curve area.
Not Provided
Interventional
Not Provided
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Breast Neoplasms
  • Device: MBI Scan: The LumaGEM®
    The LumaGEM Scanner is a dual-head, MBI scanner that has previously been cleared for medical marketing (510(k) number K111791), and has been used to image more than 5,000 patients to date. The LumaGEM MBI scanner is used as a diagnostic adjunct to mammography screening for problem cases The efficacy of MBI has been well documented in clinical trials. The LumaGEM MBI scanner is a dual-head, small field-of-view (FOV) device for developing an MBI image of Tc99m-Sestamibi uptake within the breast. The device consists of solid-state detectors, a data acquisition system, and a computer. The detectors are also used to immobilize the breast during image acquisition by mild compression. The detectors are housed in two heads that are positioned on both sides of a compressed breast.
  • Device: 3D Mammogram/Breast Tomosynthesis Scan: Selenia® Dimensions®
    The breast tomosynthesis procedure involves x-ray imaging of the breast using a moving x-ray source and digital detectors composed of cesium iodide crystals on an amorphous silicon layer or of solely selenium in order to produce an image of the breast. This procedure is considered to basically be a modification of mammography and also is used as a diagnostic adjunct to mammography screening for problem cases.
Experimental: MBI Scan & Tomosynthesis Scan
Patients will receive both scans.
Interventions:
  • Device: MBI Scan: The LumaGEM®
  • Device: 3D Mammogram/Breast Tomosynthesis Scan: Selenia® Dimensions®
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
October 2017
October 2017   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Women over 25 years of age with normal or increased risk of breast cancer.
  • Women with type 3 or 4 breast density as determined by a breast imaging radiologist on a current unilateral (women with prior mastectomy) or bilateral mammography (within prior 6 weeks).
  • No contraindications to breast MBI or breast tomosynthesis.

Exclusion Criteria:

  • Women under the age of 25.
  • Women who are or may be pregnant.
  • Women who are currently lactating or have discontinued breast feeding < 2 months prior to the study.
  • Male patients are excluded as subjects.
  • Those unable or unwilling to provide informed consent.
Female
25 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT02013726
GMI_Sc-02
No
Gamma Medica, Inc.
Gamma Medica, Inc.
Not Provided
Not Provided
Gamma Medica, Inc.
August 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP